Current cardiology reports
-
More than 200,000 people have been enrolled into clinical trials examining different reperfusion strategies for patients with acute myocardial infarction. Each year approximately 1 million people in the United States experience acute myocardial infarction. ⋯ These agents are often divided into "fibrin-specific" and "non-fibrin-specific" drugs. New thrombolytic agents designed to address several of the shortcomings of existing thrombolytics are in various stages of clinical development.
-
Ablation of reentrant ventricular tachycardia (VT) is an accepted therapy for certain patients with VT caused by coronary artery disease (CAD). Its use is currently limited to patients with sustained, monomorphic, hemodynamically tolerated VT. ⋯ Other recent studies have investigated attempted ablation of all inducible VTs in patients with multiple VT morphologies. In the future, substrate mapping may make possible ablation of VT in patients with nonsustained or fast, hemodynamically unstable VTs, thus allowing VT ablation to become a first-line therapy for many patients with VT in the setting of CAD.